Skip to main content
Clinical Trials/NCT01079559
NCT01079559
Withdrawn
Phase 3

The Effectiveness of Antibiotic Cement Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Feasibility Study

University of Western Ontario, Canada1 site in 1 countryMarch 3, 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Infection
Sponsor
University of Western Ontario, Canada
Locations
1
Primary Endpoint
relative risk of infection
Status
Withdrawn
Last Updated
13 years ago

Overview

Brief Summary

Rationale: Infection following total knee replacement (TKA) is a devastating complication that usually requires prosthesis removal, hospitalization while the infection is eradicated, and a second surgery to implant a revision prosthesis. For primary TKA, prophylactic antibiotic-loaded cement (ABC) may not only reduce the rate of infection it may also reduce the rate of revisions due to implant loosening. Current controversy about the use of ABC exists around the world. Without a definitive trial, patients will be exposed to a treatment of uncertain efficacy that may cause antibiotic resistant bacterial strains and will certainly generate high costs to the healthcare system. Purpose: To determine, 1) the extent to which ABC compared to regular cement reduces the infection rate in patients over the first two years following TKA and, 2) the resource use implications associated with the use of ABC for TKA. Methods: This is a randomized clinical trial in which 8,800 patients with undergoing primary TKA are allocated to either Simplex™ P with Tobramycin or Simplex™ P bone cement. We will exclude patients with a prior joint infection, an allergy to tobramycin, and those with no fixed address. All patients will be administered IV antibiotics immediately prior to surgery. Patients and surgeons will be blind to group allocation. The primary outcome measure is infection. Follow-up visits will take place at 6 weeks and 3, 12 and 24 months postoperative. A blinded adjudicator will review all reported infections and determine whether the putative infection is a study event. Blinded radiologists will interpret the 2 year series of radiographs for each patient. We will compare the rates of infection and implant loosening between the two treatment groups using survival analyses. This study includes a full economic analysis.

Registry
clinicaltrials.gov
Start Date
March 3, 2010
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Western Ontario, Canada
Responsible Party
Principal Investigator
Principal Investigator

Dianne Bryant

Associate Professor

University of Western Ontario, Canada

Eligibility Criteria

Inclusion Criteria

  • patients with osteoarthritis of the knee,
  • patients who are undergoing primary knee replacement,
  • patients who are able to provide informed consent.

Exclusion Criteria

  • patients with a prior joint infection,
  • patients who have a known allergy to tobramycin, and
  • patients who have no fixed address.

Outcomes

Primary Outcomes

relative risk of infection

Time Frame: 6 weeks and 3, 12 and 24 months postoperative

patients suspected of having an infected total knee replacement in the post-operative period will be evaluated clinically, and will undergo lab evaluation and an aspiration

Secondary Outcomes

  • patient-reported disease-specific health-related quality of life (HRQOL)(6 weeks and 3, 12 and 24 months postoperative)
  • cost-effectiveness(6 weeks and 3, 12 and 24 months postoperative)
  • radiographic evidence of prosthetic failure(6 weeks and 3, 12 and 24 months postoperative)

Study Sites (1)

Loading locations...

Similar Trials